15.02.2017
MorphoSys AG DE0006632003
DGAP-News: District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit
DGAP-News: MorphoSys AG / Key word(s): Patent
District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit
15.02.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, February 15, 2017
District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit
with Janssen Biotech and Genmab
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced that it has added a second patent with US Patent Number 9,200,061
to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims
methods of treating hematologic cancer associated with the undesired
presence of CD38-positive cells by administering antibodies that bind to a
specific region of the target molecule, CD38. In a hearing that took place
on February 6, 2017 the District Court granted MorphoSys's request to add
the 9,200,061 patent to the case.
On April 4, 2016 MorphoSys filed a lawsuit in the United States (U.S.)
District Court of Delaware against Janssen Biotech, and Genmab, A/S for
patent infringement of U.S. Patent Number 8,263,746.
By its complaint, MorphoSys seeks redress for infringement by Janssen's and
Genmab's daratumumab, a CD38-directed monoclonal antibody indicated for the
treatment of certain patients with multiple myeloma. Janssen Biotech
obtained FDA approval on daratumumab and markets the product as Darzalex(R)
in the U.S. and other countries. MorphoSys continues to develop MOR202, its
own investigational human antibody to CD38, for the treatment of cancer,
including multiple myeloma.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
Darzalex(R) is a registered trademark of Johnson & Johnson.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
15.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
544433 15.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR